Date published: 2026-3-31

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr1384 Inhibitors

Olr1384 inhibitors are a distinct class of chemical compounds that are specifically designed to target and inhibit the Olr1384 receptor, an olfactory receptor within the G protein-coupled receptor (GPCR) superfamily. These receptors are fundamental components of the olfactory system, which is responsible for detecting and interpreting a wide range of odorant molecules, ultimately leading to the perception of smells. Olr1384 inhibitors function by binding to the receptor's active site, where natural odorant molecules would typically interact, or by engaging with allosteric sites that can modulate the receptor's activity. This binding action effectively blocks the receptor from undergoing the conformational changes necessary to activate intracellular signaling pathways, thereby preventing the transmission of olfactory signals. As a result, these inhibitors disrupt the normal function of the Olr1384 receptor in the sensory processing of smells. The design and development of Olr1384 inhibitors are often informed by detailed structural studies of the receptor, utilizing advanced techniques such as X-ray crystallography, molecular modeling, and cryo-electron microscopy. These techniques provide crucial insights into the receptor's binding pockets and other structural features, enabling the creation of inhibitors that are highly specific to the Olr1384 receptor and effective in modulating its activity.

Chemically, Olr1384 inhibitors exhibit a diverse range of molecular structures, reflecting the various strategies used in their synthesis and design. These compounds may be small, lipophilic molecules capable of easily penetrating cellular membranes to reach their target receptors, or they may be larger, more complex structures that require sophisticated synthetic techniques to optimize their binding affinity and specificity. The synthesis of Olr1384 inhibitors typically involves multiple steps of organic chemistry, including the construction of molecular frameworks and the incorporation of functional groups that enhance the compound's interaction with the receptor. After synthesis, these inhibitors undergo rigorous characterization using a variety of analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC). These methods are employed to ensure that the inhibitors possess the desired structural integrity, purity, and inhibitory potency. The study of Olr1384 inhibitors is crucial for advancing our understanding of the specific mechanisms by which this olfactory receptor functions and how its activity can be modulated by small molecules. Additionally, this research contributes to the broader field of GPCR biology, offering valuable insights into the molecular processes underlying sensory perception, particularly within the context of olfaction. By deepening our knowledge of how olfactory receptors operate and how they can be selectively targeted, scientists can explore new directions in the study of sensory systems and the complex biochemical pathways that govern them.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

EGFR inhibitor, could inhibit growth signal pathways in non-small cell lung cancer.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 inhibitor, may target cell proliferation in breast cancer.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

BCR-ABL tyrosine kinase inhibitor, potentially effective in chronic myeloid leukemia.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

EGFR inhibitor, designed to target T790M mutation in non-small cell lung cancer.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, possibly halts cell cycle progression in breast cancer.

AP 24534

943319-70-8sc-362710
sc-362710A
10 mg
50 mg
$175.00
$983.00
2
(1)

Multi-targeted kinase inhibitor, could affect cell signaling in leukemia.

Regorafenib

755037-03-7sc-477163
sc-477163A
25 mg
50 mg
$320.00
$430.00
3
(0)

Multi-kinase inhibitor, might disrupt angiogenesis and tumor growth.

Sunitinib Malate

341031-54-7sc-220177
sc-220177A
sc-220177B
10 mg
100 mg
3 g
$197.00
$520.00
$1093.00
4
(1)

Multi-targeted receptor tyrosine kinase inhibitor, could inhibit tumor growth and angiogenesis.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

MEK inhibitor, designed to interfere with cell signaling in melanoma.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor, potentially induces apoptosis in chronic lymphocytic leukemia.